Novel bis-, tris-, and tetrakis-tertiary amino analogs as antagonists at neuronal nicotinic receptors that mediate nicotine-evoked dopamine release

https://doi.org/10.1016/j.bmcl.2010.11.070Get rights and content

Abstract

A series of tertiary amine analogs derived from lead azaaromatic quaternary ammonium salts has been designed and synthesized. The preliminary structure–activity relationships of these new analogs suggest that such tertiary amine analogs, which potently inhibit nicotine-evoked dopamine release from rat striatum, represent drug-like inhibitors of α6-containing nicotinic acetylcholine receptors. The bis-tertiary amine analog 7 exhibited an IC50 of 0.95 nM, while the tris-tertiary amine analog 19 had an IC50 of 0.35 nM at nAChRs mediating nicotine-evoked dopamine release.

Graphical abstract

A series of tertiary amine analogs derived from lead azaaromatic quaternary ammonium salts has been designed and synthesized. The bis-tertiary amine analog 7 exhibited an IC50 of 0.95 nM, while the tris-tertiary amine analog 19 had an IC50 of 0.35 nM at nAChRs mediating nicotine-evoked dopamine release.

  1. Download : Download high-res image (65KB)
  2. Download : Download full-size image

Section snippets

Acknowledgment

This work was supported by NIH. (Grant U19DA017548)

References and notes (25)

  • J.A. Dani et al.

    Pharmacol. Biochem. Behav.

    (2001)
  • N.L. Benowitz

    Am. J. Med.

    (2008)
  • R.C. Pierce et al.

    Neurosci. Biobehav. Rev.

    (2006)
  • L.P. Dwoskin et al.

    Bioorg. Med. Chem. Lett.

    (2004)
  • J.T. Ayers et al.

    Bioorg. Med. Chem. Lett.

    (2002)
  • G.R. Zheng et al.

    Bioorg. Med. Chem. Lett.

    (2007)
  • G.R. Zheng et al.

    Bioorg. Med. Chem. Lett.

    (2007)
  • Z.F. Zhang et al.

    Bioorg. Med. Chem. Lett.

    (2008)
  • S. Rahman et al.

    Neuropharmacology

    (2007)
  • W.J. Geldenhuys et al.

    Bioorg. Med. Chem.

    (2005)
  • L.P. Dwoskin et al.

    J. Pharmacol. Exp. Ther.

    (2001)
  • L.P. Dwoskin et al.

    Ann. N. Y. Acad. Sci.

    (1999)
  • Cited by (7)

    • Scientific overview: 2013 BBC plenary symposium on tobacco addiction

      2014, Drug and Alcohol Dependence
      Citation Excerpt :

      The resulting analogs should have good water-solubility, and cross the BBB independently of choline transporters due to passive diffusion through lipid membranes. Evaluation of a small library of these tertiary amine analogs as antagonists at α6β2* nAChRs identified several bis-analogs with IC50 values in the low nM or sub-nM range (Zhang et al., 2011). Two of these bis molecules: r-b3,5L/3PiDDB and r-bPiDDB (Fig. 2) are chemically reduced analogs of bPiDDB, and both compounds potently and selectively inhibit nicotine-evoked [3H]-DA release (IC50 = 0.009–0.058 nM; Imax = 60–74%) at α-CtxMII-sensitive α6β2* nAChRs (Dwoskin et al., 2009; Smith et al., 2010).

    • Nicotinic receptor antagonists as treatments for nicotine abuse

      2014, Advances in Pharmacology
      Citation Excerpt :

      Also, we were aware that the reductive agent to be utilized should be one that would not compromise linkers and/or scaffolds that incorporated double or triple bonds. A suitable reduction methodology utilizing NaBH4 was developed that rapidly and efficiently converted pyridinium and isoquinolinium headgroups into corresponding 1,2,5,6-tetrahydropyridine and 1,2,3,4-tetrahydroisoquinoline headgroups (Zhang et al., 2011). This methodology was selective for azaaromatic moieties and also useful for the reduction of 3-substituted pyridinium headgroups, since the residual double bond in the reduced headgroup prevented the generation of a chiral carbon at C3 of the pyridine ring in the reduced product.

    • Progress and challenges in the study of α6-containing nicotinic acetylcholine receptors

      2011, Biochemical Pharmacology
      Citation Excerpt :

      In addition, they identified two scaffolds with functional selectivity for α6β2* compared to α4β2* receptors (Fig. 3a and b). Zhang et al. [104] synthesized a series of tertiary amine analogs derived from lead azaaromatic quaternary ammonium salts and tested the compounds for antagonism of nicotine-evoked dopamine release. The lead compound from this series, bPiDI (Fig. 3c) antagonized dopamine release in a manner that was not additive with α-CtxMII, suggesting α6β2*-like pharmacology.

    View all citing articles on Scopus
    View full text